Spark Should Spark a Pricing Trend | Bloomberg Gadfly

Spark Therapeutics Inc. announced lower-than-expected pricing and a performance-based discount program Wednesday for its recently approved gene therapy Luxturna, a one-time treatment that helps restore sight for patients with a rare genetic condition. It’s a risky move for the company; there are very few such patients, and the price of every treatment matters a great deal.But it’s the right move, and highlights a recent trend toward (relative) pricing moderation with big implications for the drug industry.


Luxturna’s actual cost is a little less shocking in broader context. Several highly profitable rare-disease drugs — including Alexion Pharmaceuticals Inc.’s blockbuster Soliris — can approach this price, yet are designed to be taken for years. Some hemophilia treatments can be even more expensive.

Read complete article here:

Spark Should Spark a Pricing Trend – Bloomberg Gadfly.